- Home
-
Technical Platform
-
Services
- TCR-T Lead Sequence Development Service
- Immune CAR Cell Preparation Technology Service
- Antibody Coupled Drug Discovery Service
- Antibody Affinity Maturation Service
- Antibody Humanization Services
- Bispecific Antibody Development Services
- Antibody Protein Sequencing Service
- Antibody Affinity Determination Service
Antibody Drugability Evaluation Service
- Nucleic Acid Aptamer Synthesis Service
- Nucleic Acid Aptamer Modification Service
- Nucleic Acid Aptamer Library Construction Service
- Bispecific Aptamer Development Service
- Protein Nucleic Acid Aptamer Screening Service
- Metal Ion Nucleic Acid Aptamer Screening Service
- Small Molecule Nucleic Acid Aptamer Screening Service
- Cell Nucleic Acid Aptamer Screening Service
- Targeted Peptide Library Screening Service
- Targeted Peptide Library Construction Service
Targeted Peptide Discovery Technology Service
- mRNA Immune Antibody Preparation Service
- DNA Immune Antibody Preparation Service
Animal Immunization Technology Services
-
Technical Support
- Nanobody Expression in Insect Cells
- Nanobody Mammalian Cell Expression
- Single-chain Antibody Library Construction Technology Introduction
- Prokaryotic Expression of Nanobodies
- Cell Line Immunogen of Nanobody
- Construction of Single Chain Antibody Library
- Nano-antibody/Single Domain Antibody Library Construction Service
- Customized Nano-antibody Immunogen3
- Customized Nano Antibody Immunogen 2
- Customized Nano Antibody Immunogen 1
- Common Problems and Solutions of Prokaryotic Expression of Recombinant Protein
- Neutralizing Monoclonal Antibody Development Service FAQ
- A Brief Discussion on Prokaryotic Expression of Recombinant Antibodies
- Common Problems and Solutions for Recombinant Antibody Yeast Expression Experiments
- Common Problems and Solutions for Recombinant Antibody Expression Experiments in lactation
- Recombinant Single-chain Antibodies Preparation Related Issues
- Common Problems and Solutions for Prokaryotic Expression Experiments of Recombinant Antibodies
- Recombinant Single-chain Antibody Preparation
- Pharmacokinetics and bioanalysis of PEG-modified drugs
- CCR5 Receptor Recombinant Protein Key to Chemokines
Special topic on antibody modification
- Application And Prospects of CAR-T Technology in Tumor Immunotherapy
- CAR-T Lead Molecule Discovery Service
CAR Lead Antibody Molecular Discovery Service Special Topic
- Common Problems and Solutions for Yeast Two-hybrid Experiments
- Yeast Two-hybrid Technique Related Issues
- Common Problems and Solutions of Yeast Display Technology
- Overview of Yeast Two Hybrid System Principle and Application
- Introduction to Yeast Display Antibody Screening Technology
- Overview of Yeast Display Technology
- Overview of Yeast Two Hybrid Technology
- Yeast Display Platform for Rapid Nanobody Discovery
- What is the essential difference between antibody phage display and yeast display?
- Yeast One Hybrid FAQ
Yeast Display Technology Special Topic
- Antibody Affinity Testing(SPR)
- Hybridoma Gene Sequencing Process
- Antibody Affinity Detection (BLI)
- Antibody Affinity Test EC50
- Antibody Full Length Sequencing
Special Topic on Testing Services
- Phage Display Peptide Library Related Issues
- Phage Display Peptide Library
- Phage Display Antibody Library Technology
- Efficient Screening Methods and Research Progress of Anti-tumor Polypeptides
- Molecular Screening and Application of Targeted Peptides
- Screening Strategies for Cyclic Peptide Drugs
- Construction Method of Random Peptide Library
- Construction and Screening of Peptide Library
- Overview of Phage Displayed Peptide Library Technology
- Overview of Peptide Library Screening Methods
Special Topic on Phage Display Technology
- Issues Related to Aptamer Library Screening
- Introduction to Nucleic Acid Aptamer Library Screening Technology
- Overview of Aptamer Synthesis Technology
- Screening and optimization of nucleic acid aptamers
- Screening and Application of Peptide Aptamers
- Main Research Directions Progress and Challenges of Nucleic Acid Aptamer Screening Technology
- Research Progress of Protein Nucleic Acid Aptamer Screening
- Research Progress of Aptamer Screening-of Small Molecule Targets
- Nucleic Acid Aptamer Libraries Screening: an Efficient Method for Discovering Specific Binding Molecules
Molecular Biology Service Topics
-
Product Center
- Contact Us
Anti-FZD重组抗体|科研级 Vantictumab ( 万替妥单抗 )
询价与订购
Anti-FZD重组抗体|科研级 Vantictumab ( 万替妥单抗 )
Detailed related information
Catalog Number
TKYR1315
Alias
科研级 Vantictumab ( 万替妥单抗 ), Anti-FZD Recombinant Antibody, Research Grade Vantictumab
Molecular Name
Vantictumab
Size
1mg, 5mg
CAS Number
1345009-45-1
Isotype
IgG2 Lambda
Clonality
Monoclonal
Concentration
1mg/ml
Applications
Inhibition, Flow Cyt
Source
CHO Cells
Purity
≥95% as determined by SDS-PAGE
Buffer
Supplied in PBS, PH7.5
Target
FZD[Homo sapiens]
Sequence
Please contact our sales representative to learn more information about this reagents.
Background
Vantictumab /v?n?t?kt?m?b/ is a human IgG2 monoclonal antibody designed for the treatment of cancer. This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer. OncoMed was awarded a patent in 2016, which is set to expire in 2029.[3] In April 2017, Bayer terminated its option to license vantictumab.
Storage
该产品可在 2°C-8°C 下保存一个月，活性不会明显降低。在 -20°C 至 -80°C 下保存，可稳定保存十二个月。避免反复冻融,用冰袋运输。
NOTE
仅科研使用
Target background information
Experimental Plan&FAQ
Related products
To experience the reliable service of Tekbiotech please subscribe:
-
Antibody Discovery
-
Antibody Production
-
Antibody Modification
Contact
- Phone：400-168-8285
- Email：info@tekbiotech.com
- Address：5th Floor, Building A5, International Enterprise Community, Wuqing, Tianjin
WeChat Official Account
Technical Support
©2025Tekbiotech (Tianjin) Co., Ltd津ICP备2021009144号-1
津公网安备12011402001524号